Macular degeneration: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

24 of 38+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration

  Eqon Pharmaceuticals, Llc· Carmel, United States· US$233,247 awarded in fiscal year 2026· until Aug 2028

• NIH NEI · R01

  Metabolic tuning and signaling in retinal health and disease

  University of Wisconsin-Madison· Madison, United States· US$608,985 awarded in fiscal year 2026· until Aug 2030

• NIH NEI · R21

  Leveraging Ocular B cells to identiry antigen triggers in uveitis

  University of Colorado Denver· Aurora, United States· US$429,000 awarded in fiscal year 2026· until Aug 2028

• NIH NEI · U01

  RURAL Eye Health Study

  Southern California Eye Institute· Los Angeles, United States· US$1,089,223 awarded in fiscal year 2026· until May 2031

• NIH NEI · R01

  Identifying barriers to retinal Muller glial reprogramming

  University of California, San Diego· La Jolla, United States· US$499,606 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding retinal cell communication to counteract vision loss in aging (VisionGuard)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €263,393· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Drusen Reconstitution in an Engineered AMD Model using Retinal Pigment Epithelium (DREAM_RPE)

  Universidade Nova de Lisboa· Lisboa, Portugal· EU contribution €207,183· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Doctoral network on discovering pathomechanisms and novel drug optimization for AMD (PANDORA)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Germany· EU contribution €4,020,973· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Full field optoretinography for elderly eye health (FFORGE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Lysophagy as a new strategy for neuroprotection in dry AMD (AMD_Prog)

  Universite de Fribourg· Fribourg, Switzerland· EU contribution €307,959· until Aug 2028

10 of 349 running projects, newest first. Listed amounts together: US$183.6m + €21.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

  NCT06398080· Regeneron Pharmaceuticals· Updated 25 Nov 2024

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy

  NCT04075136· Wake Forest University Health Sciences· Updated 22 Mar 2024

  “IRB stopped study due to safety concerns before any participants were enrolled.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

  NCT07587515· Eyconis INC.· Source

• Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety

  NCT07481500· Jakkrit Juhong· Source

• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Hoffmann-La Roche· Source

• Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

  NCT04679935· Novartis Pharmaceuticals· Source

• Effect of Video Viewing on Intravitreal Injection Experience

  NCT07002372· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 24

• Paired DNA and RNA sequencing uncovers common and rare variation regulating human retinal gene expression.

  Nat Commun, May 2026

• A multi-agent system for automating scientific discovery.

  Nature, May 2026

• Zinc Supplementation Induced Transcriptional Changes in Primary Human Retinal Pigment Epithelium: A Single-Cell RNA Sequencing Study to Understand Age-Related Macular Degeneration.

  Cells, Feb 2023

See which targets of this disease your abstract mentions, and go to the people working on them.